Why the study?
Elevated STAT3 activity is implicated in diabetic cardiomyopathy, and the authors hypothesized its fibrosis-promoting and hypertrophic actions are linked to activation by EGFR.
Does blockade of STAT3 or EGFR attenuate cardiomyopathy in STZ-induced type 1 diabetic mice and cultured cardiomyocytes?
Population
Cultured cardiomyocytes challenged with high-concentration glucose and streptozotocin-induced type 1 diabetic mice
Comparison
Blockade of STAT3 or EGFR using selective inhibitors S3I-201 and erlotinib or siRNAs
Authors
Loading...
Hypothesis-generating for EGFR-STAT3 targeting in diabetic cardiomyopathy; leaves open any clinical relevance or therapeutic translation.
Does blockade of STAT3 or EGFR attenuate cardiomyopathy in STZ-induced type 1 diabetic mice and cultured cardiomyocytes?
Inhibition of the EGFR-STAT3 signaling axis attenuates structural and functional deficits in a mouse model of diabetic cardiomyopathy, suggesting a potential therapeutic target.
Luo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: